CLEC3B and COVID-19: For plasma proteins, small proteins were selectivity enriched and quantified by data independent acquisition (DIA) technology, which provided relatively deeper and complementary proteome data compared to previous study.12 Based on this strategy, unique protein signatures were discovered, such as tetranectin (TETN, CLEC3B) and cathelicidin antimicrobial peptide (CAMP), which could be used as new potential drug targets or biomarkers for COVID-19.